Salarius pharmaceuticals, inc. (FLKS)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Jun'14
Operating activities
Net loss

-7,498

-6,936

-6,145

11,990

5,031

-1,669

-8,606

-34,635

-34,388

-34,433

-34,305

-35,610

-38,169

-39,493

-39,485

-37,001

-32,716

-29,141

0

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization and impairment

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation expense

-

-

-

-

-

-

-

277

297

324

362

358

337

277

178

119

71

49

0

0

0

0

Equity-based compensation expense

754

751

557

-955

-842

30

1,005

3,377

3,939

4,219

4,472

5,328

6,243

6,572

7,071

6,717

6,369

6,597

0

0

0

0

Change in fair value of warrant liability

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization and accretion on investments

-

-

-

-

-

-

-

40

58

68

0

0

0

-

-

-

-

-

-

-

-

-

Other non-cash items

-

-

-

-

-

-

-

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

Amortization and accretion on investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

55

-

0

0

0

0

Other non-cash items

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Changes in operating assets and liabilities:
Grants receivable

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Accounts receivable

-

-

-

-

-

0

-24

-24

-13

-1

13

23

19

12

0

0

0

-

-

-

-

-

Inventory

-

-

-

-

-

0

-102

45

20

-22

424

-27

301

454

109

274

112

0

0

0

0

-

Prepaid expenses and other current assets

-359

-91

172

419

-290

239

-4

-338

-309

-148

-498

-1,050

-406

17

468

1,449

937

538

0

0

0

0

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

64

-70

-70

-70

-100

0

0

0

0

Accounts payable

-2,020

-519

-426

1,036

67

-285

641

-641

1,422

819

-286

403

-651

309

509

571

904

621

0

0

0

0

Accrued expenses and other current liabilities

503

-320

3,010

3,868

4,707

3,275

-155

-104

-494

1,124

1,409

927

988

746

878

482

516

1,570

0

0

0

0

Due to/from related party

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

80

88

0

0

0

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-23

16

68

76

50

19

-9

-8

-8

-4

-18

0

0

0

0

Other long term liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash used in operating activities

-13,419

-11,580

-8,556

18,403

11,720

4,177

-1,965

-31,474

-28,909

-27,722

-28,265

-27,466

-31,104

-32,052

-31,190

-30,641

-25,779

-20,746

0

0

0

0

Investing activities
Purchases of marketable securities

-

-

-

-

-

-

-

25,378

25,378

32,987

33,960

26,214

36,275

38,682

46,481

61,472

51,411

39,397

0

0

0

0

Proceeds from maturities and sales of marketable securities

-

-

-

-

-

-

-

33,420

55,192

57,585

54,811

54,164

34,905

26,995

16,869

25,511

20,998

12,398

0

0

0

0

Purchases of property and equipment

-

-

-

-

-

-

-

-

-

113

148

322

474

559

551

480

346

265

0

0

0

0

Proceeds from sales of property and equipment

-

-

-

-

-

-

-

3

5

5

9

8

5

5

0

0

0

-

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

0

4,662

7,986

29,728

24,489

20,712

27,635

-1,838

-12,240

-30,163

-36,441

-30,759

-27,265

0

0

0

0

Financing activities
Proceeds from issuance of equity securities, net

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on note payable

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from initial public offering, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

80,435

0

0

0

0

Proceeds from sale of restricted common stock to founders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from exercise of common stock

-

-

-

-

-

-

-

118

57

2

2

16

14

22

24

13

15

8

0

0

0

0

Proceeds from early exercise of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

400

0

0

0

-

Net cash provided by financing activities

11,687

3,579

897

1,317

2,888

1,435

1,741

118

57

2

2

16

14

22

24

13

15

80,843

0

0

0

0

Net increase (decrease) in cash, cash equivalents and restricted cash

3,875

-2,392

-2,050

5,599

2,489

5,612

4,438

-23,369

876

-3,230

0

0

0

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-61,329

-67,070

-56,522

32,832

0

0

0

0

Supplemental disclosure of cash flow information:
Cash paid for interest

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash investing and financing activities:
Accrued issuance costs for public offering

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of shares for license

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of liabilities to equity

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

IPO issuance costs paid in cash through December 31, 2014

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

575

0

0

0

0

Property and equipment purchases included in accounts payable at September 30, 2017

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

Property and equipment in accounts payable at September 30, 2015

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Property and equipment purchases included in accounts payable and accrued expenses at December 31, 2016

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

213

-

0

0

0

0

IPO issuance costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0